The positive clinical signal strengthens the value proposition of RenovoRx’s TAMP platform and IAG candidate. Traders should monitor upcoming interim or final results from the Phase III TIGeR-PaC trial as the next major catalyst, especially given orphan drug designation provides 7 years of market exclusivity upon approval.
Price Chart
Executive Summary
RenovoRx announced clinical data presented at SIR 2026 showing TAMP, enabled by its RenovoCath device, achieved reduced systemic toxicity and notable tumor activity reduction in locally advanced pancreatic cancer patients. Metabolic imaging indicated early treatment response, supporting ongoing Phase III TIGeR-PaC trial for IAG.
Key Facts
- Clinical data abstract on TAMP therapy was presented at the 2026 Society of Interventional Radiology Annual Meeting.
- TAMP enables targeted intra-arterial delivery of gemcitabine directly near tumor sites, improving drug concentration and reducing systemic exposure.
- FDG PET/CT imaging showed dramatic reductions in tumor metabolic activity, suggesting treatment response even without significant anatomical change.
- Eight cycles of intra-arterial chemotherapy were delivered via RenovoCath over two months with promising safety and efficacy signals.
- Findings support the ongoing Phase III TIGeR-PaC trial evaluating IAG (intra-arterial gemcitabine via RenovoCath) for locally advanced pancreatic cancer.
Financial Impact
No direct financial figures disclosed; potential long-term revenue upside if Phase III trial succeeds and leads to FDA approval.
Risk Factors
- Phase III trial may not confirm efficacy or safety seen in earlier studies.
- Regulatory approval of IAG is uncertain and subject to FDA review.
- Commercial success depends on adoption by oncology centers and reimbursement policies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3273372 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Press Release | $1.27 | awaiting T+60 | — | $1.39 (+9.45%) |
Jul 29, 2026 12w ago | Press Release | $0.8981 $1.27 | ▲ +41.41% | ▲ +36.68% | $1.39 (+54.77%) |
Jul 2, 2026 16w ago | 8-K | $0.9201 $1.68 | ▼ −82.59% | ▼ −79.58% | $1.39 (−51.07%) |
May 26, 2026 22w ago | Press Release | $0.9160 $1.32 | ▲ +43.56% | ▲ +40.83% | $1.39 (+51.75%) |
May 19, 2026 23w ago | Press Release | $0.8060 $1.26 | ▲ +56.33% | ▲ +50.04% | $1.39 (+72.46%) |
May 15, 2026 23w ago | 10-K/A | $0.7830 $1.12 | ▲ +43.04% | ▲ +38.19% | $1.39 (+77.52%) |
May 14, 2026 23w ago | 8-K | $0.8200 $1.15 | ▲ +40.24% | ▲ +35.73% | $1.39 (+69.51%) |
Apr 29, 2026 25w ago | Press Release | $0.8310 $0.8653 | ▲ +4.13% | ▲ +0.02% | $1.39 (+67.27%) |
Apr 28, 2026 26w ago | EFFECT | $0.8400 $0.8545 | ▲ +1.73% | ▼ −2.26% | $1.39 (+65.48%) |
Apr 16, 2026 27w ago | S-3 | $1.00 $0.8500 | ▼ −15.00% | ▼ −21.14% | $1.39 (+39.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers